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Abstract
Background: Diabetes is a chronic medical condition accompanied by a considerable health-
related quality of life (HRQL) burden. The purpose of this analysis was to use generic measures of
HRQL to describe HRQL deficits associated with varying degrees of severity of type 2 diabetes.
Methods: The RAND-12 physical and mental health composites (PHC and MHC, respectively) and
Health Utilities Index Mark 3 (HUI3) were self-completed by 372 subjects enrolled in a prospective,
controlled study of an intervention to improve care for individuals with type 2 diabetes in rural
communities. Analysis of covariance was used to assess differences in HRQL according to disease
severity and control of blood glucose. Disease severity was defined in terms of treatment intensity,
emergency room visits and absenteeism from work specifically attributable to diabetes. To control
for potential confounding, the analysis was adjusted for important sociodemographic and clinical
characteristics.
Results:  The PHC and MHC were significantly lower for individuals treated with insulin as
compared to diet alone (PHC: 41.01 vs 45.11, MHC: 43.23 vs 47.00, p < 0.05). Individuals treated
with insulin had lower scores on the vision, emotion and pain attributes of the HUI3 than individuals
managed with oral medication or diet. The PHC, MHC, pain attribute and overall score on the
HUI3 captured substantial decrements in HRQL associated with absenteeism from work due to
diabetes, while the burden associated with emergency room utilization for diabetes was seen in the
PHC and HUI3 pain attribute.
Conclusions: We concluded that generic measures of HRQL captured deficits associated with
more severe disease in type 2 diabetes.
Background
Severity of diabetes has been associated with increased
burden and impairment on many dimensions of health-
related quality of life (HRQL), including social function-
ing, cognition, role functioning, physical functioning,
emotional well-being, general perceptions of health and
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pain [1-14]. Diabetic complications, such as retinopathy,
nephropathy, neuropathy, cardiovascular disease, stroke
and peripheral vascular disease, result in significant mor-
bidity and mortality [1-9]. Self-reported HRQL is an
important outcome to assess in diabetes because clinical
parameters, such as glycated hemoglobin (HbA1c), a
measure of average blood glucose control over the previ-
ous three months, often fail to capture the overall impact
of the disease.
Commonly used indicators of disease advancement or
severity have included treatment intensity of diabetes,
duration of diabetes, number and severity of complica-
tions associated with diabetes. The presence and severity
of complications relate to clinical depression, anxiety and
impairment on both generic and disease-specific meas-
ures of health status and HRQL in individuals with type 1
or type 2 diabetes [2-5,15]. There is evidence that longer
duration of diabetes is associated with deficits in HRQL
[2,6,16,17], but some studies have failed to find this asso-
ciation [18,19].
The purpose of this analysis was to describe HRQL deficits
associated with varying degrees of disease severity and
poor control of blood glucose in type 2 diabetes, using the
RAND-12 and Health Utilities Index Mark 3 (HUI3), two
generic measures of HRQL. The prevalence of comorbidi-
ties in type 2 diabetes is relatively high. Past research sug-
gests disease-specific measures may better capture the
dimensions of HRQL most affected by diabetes, but these
measures are not designed to capture the deficits associ-
ated with comorbidities, i.e. they are specific to diabetes.
Generic measures may be useful for capturing the addi-
tional HRQL deficits associated with comorbidities, such
as cardiovascular disease and depression, as they encom-
pass a broad range of dimensions or attributes of HRQL.
Further, using generic measures often enables compari-
sons to be made between the study sample and available
population norms. Finally, preference-based measures,
such as the HUI3, can provide utility scores for varying
degrees of disease severity, which may be incorporated
into cost utility analyses. We hypothesized that generic
measures would capture increasing HRQL deficits accord-
ing to disease severity, and that the HUI3 may be more
sensitive than the RAND-12, as the HUI3 has attributes
that may be directly affected by diabetic complications.
Methods
Study Design
This analysis was conducted using baseline, cross-sec-
tional data from a prospective, controlled study of an
intervention to improve care for individuals with type 2
diabetes [20]. Two comparable and geographically adja-
cent rural health regions in Northern Alberta were
included in the intervention study. The intervention
region had a population of 20,000 residents, 17 physi-
cians, and one full-time and two part-time diabetes edu-
cators, while the control region had a population of
25,000 residents, 22 physicians, and one part-time diabe-
tes educator. Both regions were about a six hour drive
from the nearest secondary or tertiary care referral centres.
In both regions approximately 75% of the population was
white and 25% was First Nations (aboriginal). Ethical
approval for the study was obtained through the Univer-
sity of Alberta Health Research Ethics Board Panel A.
Sample
Three hundred and ninety-three individuals with type 2
diabetes were enrolled in the main study. In order to be
included in the study, subjects had to have type 2 diabe-
tes, live within the control or intervention region, consent
to baseline measurements, be sufficiently literate in Eng-
lish to answer surveys and be willing to participate in fol-
low-up visits. Subjects were excluded if they were
discovered to not have type 2 diabetes, had a foreshort-
ened life-expectancy, declined enrollment or were unable
or unwilling to give informed consent. Subjects were
recruited and enrolled by local diabetes health care pro-
fessionals (registered dieticians, certified diabetes educa-
tors, registered diabetes nurses), diabetes education
programs, community pharmacists or primary care
physicians.
Measures
The RAND-12 and HUI3 were used to measure the HRQL
deficits experienced by patients. Both HRQL measures
were self-administered, self-completed at the time of the
baseline visit or were submitted via mail. For both HRQL
measures, we used the standard four week recall.
The HUI3 is a preference-based index measure of HRQL
that uses a multi-attribute utility function to assign valua-
tions to different health states [21]. Using the multi-
attribute approach, health states are defined by a classifi-
cation system that includes a set of dimensions or
attributes of HRQL, with a number of different levels of
functioning for each attribute. In the HUI3 system, eight
attributes, including vision, hearing, speech, ambulation,
dexterity, emotion, cognition and pain and discomfort,
define health status. Each attribute has five or six levels,
which creates 972,000 unique HUI3 health states. Within
each attribute, levels range from highly impaired (e.g.
blind for vision) to normal. Overall utility scores on the
HUI3 range from -0.36 to 1.0, with -0.36 representing the
utility of the worst possible HUI3 health state, 0.0 repre-
senting dead and 1.0 representing perfect health [21]. Dif-
ferences of greater than 0.03 on the overall HUI3 score are
considered clinically important [22,23].Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/78
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In addition to overall scores, single attribute utility scores
(SAU) can be obtained for each attribute of the HUI3 [21].
For the single attribute utilities, scores range from 0.0 to
1.0, with a score of 0.0 representing the lowest level of
functioning on an attribute and a score of 1.0 representing
full functional capacity on an attribute. Differences in
SAU scores of 0.05 may be considered clinically important
[23]. The HUI3 may be particularly useful in studying
HRQL in diabetes because several of the single attributes
would likely be affected by severity of diabetes and dia-
betic complications. Thus, we focused on the vision,
ambulation, dexterity, cognition and pain attributes in the
analysis.
The RAND-12 contains 12 items taken from the eight
scales of the RAND-36 Health Status Inventory (RAND-
36) [24] and measures physical and mental dimensions of
health status. Six of the 12 items create the Physical Health
Composite (PHC) and the remaining six items create the
Mental Health Composite (MHC). Scoring of each scale
uses a one-parameter Rasch model, based on item
response theory. The PHC and MHC are norm-based
standardized scores, with a mean of 50 and standard devi-
ation of 10 (i.e. T-scores) in the general United States pop-
ulation [24]. The RAND-12 uses the same 12 items of the
commonly recognized SF-12 [25], but applies a different
scoring algorithm. We found the RAND-12 scoring
approach performed better than the SF-12 in discriminat-
ing known groups in this sample [26]. While a minimally
clinically important difference on the RAND-12 has not
been clearly defined, a difference between groups of 5.0
would represent a moderate effect size (0.50) (mean dif-
ference = 5.0 / S.D. = 10.0 = 0.50), which may be consid-
ered clinically important.
Severity at the time of the survey was defined in terms of
treatment intensity of diabetes, self-reported emergency
room utilization specifically related to diabetes in the pre-
vious six months, and self-reported absenteeism from
work specifically related to diabetes in the previous six
months. Management of diabetes with diet alone was
defined as the least intense treatment, followed by oral
medications, while the most intense treatment was with
insulin alone or in combination with oral medications.
Data on treatment intensity, duration of diabetes, emer-
gency room visits and absenteeism from work were self-
reported.
Control of blood glucose was assessed using glycated
hemoglobin (HbA1c), a measure of average control of
blood glucose over the previous three months. For
HbA1c, we categorized individuals according to targets
from the clinical practice guidelines for diabetes manage-
ment in Canada that were current during the time of the
study [8]. Glycated hemoglobin of less than 0.070 was the
optimal target goal, 0.071 to 0.084 to indicative of less-
than optimal control possibly warranting action, and
greater than 0.084 was indicated inadequate control and
that action should be taken [8]. Blood samples for gly-
cated hemoglobin levels were all drawn in labs in North-
ern Alberta and the analysis of samples was carried out in
a central lab, where the range of normal values for this
measure was 0.043 to 0.061.
Statistical Significance Testing
Analysis of covariance (ANCOVA) was used to assess dif-
ferences in HRQL associated with varying degrees of dis-
ease severity and control of blood glucose. For treatment
intensity, individuals treated with insulin were presumed
to have the most severe disease and largest disease burden,
while individuals managed using diet alone were pre-
sumed to be the least burdened by diabetes. Among those
subjects who indicated they were employed, individuals
who attributed an absenteeism from work to diabetes
were anticipated to have greater disease burden than indi-
viduals who did not. Similarly, individuals who visited an
emergency room due to diabetes were expected to have a
greater burden. It was anticipated that the relationship
between control of blood glucose and HRQL, if present at
all, would be weak.
In order to control for potential confounding, age, sex,
level of education, annual household income, body mass
index, and ethnicity (aboriginal or First Nations versus
caucasian) were entered as covariates in all analyses.
Duration of diabetes was controlled for in the analyses for
emergency room visits, days off work, and control of
blood glucose, but was not controlled for in the analysis
for treatment intensity. A high correlation between treat-
ment intensity and duration of diabetes suggested colline-
arity would be a problem in the analysis; therefore,
duration of diabetes was excluded from this analysis. For
all comparisons, a p-value of less than 0.05 (two-tailed)
was considered to be statistically significant.
For interpreting clinically important differences on the
PHC and MHC of the RAND-12, Cohen's guidelines for
effect sizes were used as no established guidelines were
available. Effect sizes of greater than 0.80 were considered
large, while effect sizes between 0.50 and 0.79 were con-
sidered moderate and effect sizes between 0.20 and 0.49
were considered small [27].
Statistical analyses were performed using SPSS Version
11.5 with the available cases. No data was imputed for
this cross-sectional analysis.
Results
Of the 393 subjects originally enrolled in the original
study, 372 (94.7%) completed baseline HRQLHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/78
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questionnaires. No statistically significant differences in
age, sex, level of education, income, BMI and duration of
diabetes were noted between individuals who did (n =
372) and did not (n = 21) complete baseline HRQL data.
The percentage of the study sample with HRQL data miss-
ing ranged from a low of 1.9% (n = 7) for the emotion and
dexterity attributes of the HUI3 to a high of 14.8% (n =
55) for the overall HUI3 score. If an individual's level was
missing for any of the HUI attributes, the overall score
would be missing. Of those who had completed the base-
line surveys (N = 372), individuals missing the PHC,
MHC and overall HUI3 scores were statistically signifi-
cantly older and had lower incomes than individuals with
complete data. In addition, individuals with missing
HRQL data were more likely to be widowed. For the vari-
ables used to separate the sample into known groups,
individuals with missing HUI3 scores tended to have
more intensive treatment of their diabetes, i.e. they were
more likely to use insulin and/or oral medications than to
be managed on diet alone.
The majority of the sample was female (53.3%), currently
married (68.3%), and had not completed high school
(67.2%). A considerable proportion of the sample was
retired (43.5%), which is not surprising as the average age
of the sample was 62.3 ± 12.53 years. Approximately one-
quarter (26.6%) of the study sample was First Nations
(aboriginal). The average duration of diabetes was 8.0 ±
8.5 years, with the most common treatment for diabetes
being oral medications, although a substantial proportion
of the sample (27.2%) was treated with insulin. Overall,
the unadjusted mean PHC (43.48 ± 10.81) was slightly
lower than the MHC (44.84 ± 10.24) for the study sample,
though both composites were approximately one-half of
a standard deviation below the general United States pop-
ulation norm of 50. The average unadjusted overall HUI3
score was 0.64 ± 0.30.
When demographic and clinical variables were compared
according to treatment intensity, the groups were similar
for the most part. Differences were not statistically signif-
icant for most variables, with the exception of duration of
diabetes, control of blood glucose, and main activity
(Table 1). The average duration of diabetes of individuals
whose diabetes was managed using insulin with or with-
out oral medication was almost five times that of individ-
uals whose diabetes was managed with diet alone (Table
1).
Burden Associated with Disease Severity
The burden associated with severity of type 2 diabetes was
reflected in both physical and mental dimensions of
HRQL (Table 2 and Table 3). In comparing those man-
aged with diet alone to those using insulin, a statistically
significant difference (p < 0.05) of 4.10 units (95% CI:
0.49–7.72) was observed in the PHC, representing a small
to moderate effect size, after adjusting mean scores for the
Table 1: Baseline Demographic, Clinical and HRQL Characteristics According to Treatment Intensitya
Diet n = 69 (17.5%) Oral Medication n = 190 (48.2%) Insulin n = 107 (27.2%)
Age – Mean (SD) 60.13 (12.20) 63.44(12.78) 62.67 (12.10)
Sex, Males – n (%) 34(49.3) 81 (42.6) 45 (42.1)
Income – n (%)
less than $5000 4 (5.8) 16 (8.4) 12 (11.2)
$5000 to $19999 18 (26.1) 64 (33.7) 39(36.4)
$20000 to 399999 21 (30.4) 45 (23.7) 24(22.4)
greater than $40000 19 (27.5) 48 (25.3) 18(16.8)
Marital status, Currently married – n (%) 45 (65.2) 121 (63.7) 58 (54.2)
First Nations Status – n (%) 17 (24.6) 38 (20.0) 32 (29.9)
Graduated high school – n (%) 44 (33.8) 66 (34.7) 30 (28.0)
Main activityb – n (%)
Retired 25 (36.2) 85 (44.7) 42 (39.3)
Working for pay 30 (43.4) 55 (29.0) 24 (22.5)
Other 13 (18.7) 40 (22.4) 41 (38.3)
Duration of diabetesc (years) – Mean (SD) 3.17 (5.75) 6.28 (6.19) 14.89 (9.46)
HbA1c (%) c – Mean (SD) 0.064 (0.011) 0.073 (0.015) 0.082 (0.017)
Body Mass Index (kg/m2) – Mean (SD) 34.65 (6.19) 32.48 (6.93) 33.89 (7.17)
Total Cholesterol (mmol/L) – Mean (SD) 5.02 (0.92) 4.88 (0.97) 5.05 (1.06)
Systolic Blood Pressure (mmHg) – Mean (SD) 129.62 (17.45) 131.88 (17.12) 132.66 (22.39)
Diastolic Blood Pressure (mmHg) – Mean (SD) 77.74 (12.99) 76.46 (10.68) 74.13 (11.96)
a Table includes those subjects with complete data on treatment regimen for diabetes (N = 366/372) b Chi-Square p-value = 0.001c Omnibus 
ANOVA had p < 0.001 and all post-hoc pair-wise comparisons had p ≤ 0.01Health and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/78
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covariates. As well, the difference in overall HUI3 score
between management with diet alone and insulin was
clinically important and statistically significant (0.68 vs
0.61, p < 0.05, 95% CI for difference: -0.04 – 0.17). Statis-
tically significant and clinically important differences
were also observed for the vision and pain attributes of the
HUI3, both of which reflect the physical dimension of
HRQL. The difference in vision scores between individu-
als managed with diet alone compared to insulin was
0.07, while the difference in the pain attribute between
individuals whose treatment regimen included insulin as
compared to oral medication was 0.08.
Scores on the MHC of the RAND-12 and the HUI3 emo-
tion attribute were both highest for subjects whose diabe-
tes was managed with diet alone. The magnitude of the
difference in MHC for individuals managed with diet
alone compared to insulin was 3.77 units (effect size =
0.38, p < 0.05), which was slightly smaller than the differ-
ence in PHC between these groups. Also clinically impor-
tant and statistically significant was the difference in
scores on the HUI3 emotion attribute (0.07, p < 0.05) for
individuals being managed with insulin compared to diet
alone.
The HRQL burden of individuals who required an absen-
teeism from work due to diabetes was substantial (Table
3). Differences between individuals who were and were
not absent from work for the PHC and MHC were 13.07
(p < 0.001, effect size = 1.3) and 6.29 (p = 0.084, effect
size = 0.63), respectively, representing moderate to large
effect sizes. Clinically important and statistically signifi-
cant differences in overall HUI3 scores were also observed
between individuals who were and were not absent from
work due to diabetes (0.23, p < 0.001). The difference in
the pain attribute of the HUI3 was considerable (0.28, p <
0.001), further demonstrating the physical health burden
associated with greater disease severity.
The PHC was significantly lower for individuals who
reported one or more emergency room visits for diabetes
(37.68) compared to individuals who reported no emer-
gency room visits (44.28, p < 0.05) (Table 3). The effect
size for this difference was moderate to large (0.66). The
HUI3 pain attribute was also affected; the difference
between groups was 0.16 (p < 0.05), three times the
threshold of what would be considered clinically impor-
tant. In contrast to missing work due to diabetes, the need
to visit an emergency room for diabetes was not associ-
ated with a significant mental health burden on the HUI3,
which assesses happiness or depression. While the differ-
ence in scores on the MHC of the RAND-12 between sub-
jects who did and did not have an emergency room visit
for diabetes did not reach statistical significance, the effect
size was moderate (0.53) (Table 3).
Burden Associated with Poor Control of Blood Glucose
As hypothesized, differences in HRQL between individu-
als in the three categories of control of blood glucose
(optimal target goal, less-than optimal control possibly
warranting action, and inadequate control that requires
action) were negligible for the most part, after adjusting
for the covariates in the model. A clinically important dif-
ference on the pain attribute, however, was observed
between individuals who had acceptable control
(adjusted mean = 0.83, 95% CI: 0.78–0.87) or whose con-
trol of blood glucose suggested that action may be
required (adjusted mean = 0.83, 95% CI: 0.77–0.88) and
Table 2: Comparison of adjusted meana (95% CI) HRQL scores for treatment regimen for diabetes
Diet Only
(n = 55–60)b
Oral Medication
(n = 141–158)b
Insulin Alone or with oral medication
(n = 63–76)b
Adjusted Mean Difference (95% CI) for 
largest difference between groups
RAND 12
PHC d 45.11 43.98 41.01 4.10 (0.49–7.72) c
MHC e 47.00 44.92 43.23 3.77 (0.31–7.23) c
Health Utilities Index
HUI3 Overall Utilityf 0.68 0.64 0.61 0.07 (-0.04–0.17)
HUI3 Single Attribute Utility Scores
Utility Scores
Visionf 0.94 0.91 0.87 0.07 (0.02–0.12) c
Ambulationg 0.93 0.94 0.91 0.03 (-0.05-0.04)
Dexterity 0.96 0.97 0.94 0.03 (-0.02–0.07)
Emotion h 0.93 0.88 0.86 0.07 (0.002–0.13) c
Cognition i 0.91 0.89 0.90 0.02 (-0.30-0.07)
Pain f 0.80 0.84 0.76 0.08 (0.012–0.15) c
a Covariates included income, age, BMI, First Nations Status, sex and education b n varied depending on number of individuals with missing data for 
each global, single attribute utility, and health composite score c p < 0.05 d Statistically significant covariates (p < 0.05) included high school 
graduation, income and BMI e Statistically significant covariates (p < 0.05) included BMI f Statistically significant covariates (p < 0.05) included 
income g Statistically significant covariates (p < 0.05) included BMI and age h Statistically significant covariates (p < 0.05) included First Nations 
Status i Statistically significant covariates (p < 0.05) included high school graduationHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/78
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those whose control of blood glucose suggested action
was required (adjusted mean = 0.77, 95% CI: 0.69–0.83).
These differences failed to reach statistical significance.
Discussion
Type 2 diabetes is a progressive disease in which advanc-
ing condition or severity is generally presumed to have an
increasing burden on overall health. In this study, we
found the burden associated with severity of type 2 diabe-
tes generally affected physical and mental dimensions of
health status and HRQL, as measured by the RAND-12
and HUI3. As anticipated, control of blood glucose, meas-
ured using HbA1c, was not a significant indicator of the
self-reported HRQL burden of type 2 diabetes, regardless
of its association with the development of long-term
microvascular complications.
We were confident that treatment intensity of diabetes
could be used as a marker of disease severity in type 2 dia-
betes as the Canadian Diabetes Association, until its
December 2003 Guidelines, had recommended a step-
wise approach to the management of type 2 diabetes start-
ing with diet alone, then progressing to oral medications
and, finally, to insulin with or without oral medications
[8]. Further supporting the use of treatment intensity as a
marker of disease severity in our data was the observation
that individuals who were treated with insulin were also
treated, on average, with a larger number of antihyperten-
sive medications (p = 0.008) and were more difficult to
control adequately (i.e. higher HbA1c) (p < 0.001). As
well, a larger proportion of individuals taking oral medi-
cations for diabetes (23.8%) or insulin alone or in combi-
nation with oral medication (29.9%) received a lipid
lowering medication (specifically HMG-CoA Reductase
Inhibitors), compared to individuals whose diabetes was
managed by diet alone (13.0%) (p = 0.036). This suggests
higher rates of comorbidity or more aggressive treatment
in the higher treatment intensity groups.
Table 3: Comparison of adjusted meana HRQL scores according to emergency room visits and days off work for diabetes
Days off Work for Diabetes No days off work for diabetes
(n = 77–84)b
One or more days off work for diabetes
(n = 9)
Adjusted Mean Difference
(95% CI)
RAND 12
PHC c 48.92 35.85 13.07 (5.66–20.49)d
MHC e 46.99 40.70 6.29 (-0.86–13.44)
Health Utilities Index
HUI3 Overall Utility 0.76 0.53 0.23 (0.29–0.43) f
HUI3 Single Attribute Utility Scores
Utility Scores
Vision 0.93 0.97 0.04 (-0.10-0.03)
Ambulation 0.99 0.98 0.01 (-0.03–0.05)
Dexterity g 0.99 0.97 0.02 (-0.01–0.05)
Emotion 0.92 0.84 0.08 (0.0002–0.17)f
Cognition 0.92 0.94 0.02 (-0.12-0.08)
Pain 0.89 0.61 0.28 (0.11–0.45) d
ER Visits for Diabetes No ER visits for diabetes
(n = 241–272)b
One or more ER visits for diabetes
(n = 13–21)b
Adjusted Mean Difference
(95% CI)
RAND 12
PHC h 44.28 37.68 6.60 (0.65–12.55) f
MHC i 45.63 40.29 5.34 (-0.63–10.77)
Health Utilities Index
HUI3 Overall Utility j 0.66 0.50 0.16 (0.002–0.33) f
HUI3 Single Attribute Utility Scores
Utility Scores
Vision k 0.91 0.93 0.02 (-0.01–0.06)
Ambulation l 0.93 0.89 0.04 (-0.03–0.12)
Dexterity 0.96 1.00 0.04 (-0.11-0.03)
Emotion m 0.88 0.85 0.03 (-0.06–0.13)
Cognition n 0.91 0.87 0.04 (-0.05–0.12)
Pain j 0.84 0.67 0.17 (0.03–0.30) f
a Covariates included income, age, BMI, First Nations Status, sex, education, and duration of diabetes b n varied depending on number of individuals 
with missing data for each global, single attribute utility, and health composite score c Statistically significant covariates (p < 0.05) included BMI d p 
< 0.001 e Statistically significant covariates (p < 0.05) included age f p < 0.05 g Statistically significant covariates (p < 0.05) included sex and income 
h Statistically significant covariates (p < 0.05) included high school graduation, BMI and duration of diabetes i Statistically significant covariates (p < 
0.05) included BMI and education j Statistically significant covariates (p < 0.05) included income k Statistically significant covariates (p < 0.05) 
included income and duration l Statistically significant covariates (p < 0.05) included age and BMI m Statistically significant covariates (p < 0.05) 
included First Nations Status n Statistically significant covariates (p < 0.05) included high school graduationHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/78
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Treatment with insulin, as a marker for disease severity,
was associated with increased physical and mental health
burden. Individuals treated with insulin were almost one
standard deviation below population norms on the PHC,
suggesting a large effect. Further, insulin use was associ-
ated with nearly a seven point deficit on the MHC relative
to the population norm, representing a moderate to large
effect. Deficits in health status were smaller in less intense
treatment groups relative to the population norms for
each composite (i.e. the T-Score of 50).
Although the comparison between diet alone and the
insulin treatment groups was statistically significant for
both the PHC and MHC, the effect size was small to mod-
erate. For the HUI3, however, differences in the overall,
vision, pain and emotion single attribute scores were rela-
tively large and exceeded the difference that would be con-
sidered clinically important. The difference between
individuals managed with diet alone compared to oral
medication were relatively small for the PHC and MHC of
the RAND-12, but the difference in overall HUI3 score
achieved clinical importance. Thus, the HUI3 may be
more sensitive than the RAND-12 to the burden associ-
ated with increased severity of type 2 diabetes.
Our findings for treatment intensity are consistent with
previous research in that increased intensity of treatment
(i.e. progressing from diet to oral medications and finally
to insulin) in individuals with type 2 diabetes has been
associated with lower levels of HRQL in previous cross-
sectional studies [3,4,6]. However, when the UKPDS
examined treatment intensity of type 2 diabetes longitudi-
nally, it was found that intensive policies to manage
blood glucose did not adversely affect HRQL [28]. Thus,
the relationship between increased intensity of treatment
and decreased HRQL could be attributable to increased
treatment burden, but may also reflect the fact that more
intense treatment is associated with more advanced or
severe disease.
It was hypothesized that emergency room visits and days
off work attributable to diabetes would be related to a dia-
betic complication or comorbidity, and, thus, these varia-
bles could be used as additional markers for varying
degrees of disease severity as no direct measures were
available in the data. The physical and mental health bur-
den associated with emergency room visits and time off
work for diabetes was significantly larger than the burden
seen for treatment regimen. The effect size of the differ-
ence in disease burden was large according to absentee-
isms from work and emergency room visits for diabetes.
The need for time off work or an emergency room visit
was associated with MHC scores approximately 1.0 and
PHC scores approximately 1.2 to 1.4 standard deviations
below the population norms of 50 for each composite.
This suggests having severe disease was associated with
substantial burden, both physical and mentally, relative
to the population from which the norms for the RAND-12
were derived.
Emergency room visits due to diabetes were associated
with a larger physical health deficit than mental health
burden for the RAND-12. The deficits observed on overall
HUI3 scores associated with emergency room visits and
absenteeism from work appeared to be driven mainly by
the pain attribute. Differences in the remaining single
attributes were small, with the exception of the differences
in the emotion attribute according to absenteeism from
work, which was clinically important and statistically
significant.
Only small variations in HRQL scores were seen for indi-
viduals according to the three Hb1Ac groups, with the
exception of the pain attribute. Thus, the burden associ-
ated with poor control of blood glucose was not captured
by cross-sectional assessment of HRQL using the RAND-
12 PHC, MHC, overall HUI3 or any of the remaining sin-
gle attributes. This may suggest that the generic measures
of health status that were used were not sensitive enough
to detect differences between these groups, a result similar
to previous research using other generic measures of
HRQL in diabetes [28-31]. Generally, generic measures
have failed to demonstrate an association between HRQL
and HbA1c, while specific measures of HRQL have more
frequently demonstrated a significant relationship
between HRQL and control of blood glucose [15,32,33].
The failure to demonstrate a relationship between HRQL
and control of blood glucose in this study could attribut-
able to other factors unrelated to the instruments. The lack
of an observed relationship could be due to a weak rela-
tionship between control of glucose and HRQL or due to
the use of average control over three months (HbA1c),
rather than episodes of hyperglycemia or hypoglycemia
[33]. Indicators of unstable control may better reflect the
overall disease burden of diabetes rather than average
control of blood glucose over a three month period. While
HbA1c is associated with complications and microvascu-
lar complications are associated with HRQL, evidence for
the direct association between HbA1c and HRQL cross-
sectionally is not strong.
After controlling for a number of important determinants
of health that would likely affect health status and HRQL
(e.g. sex, education, income, body mass index), we dem-
onstrated important differences in HRQL for different lev-
els of diabetes severity. We also demonstrated the ability
of these widely used HRQL measures to pick up these dif-
ferences. Generic, utility-based HRQL scores, such as the
HUI3, are important in that they can be incorporated into
quality-adjusted life years and economic evaluations ofHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/78
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health care interventions. Unfortunately, the use of prefer-
ence-based measures in diabetes has been limited. In fact,
a review of the literature only produced a limited number
of studies which used a preference-based measure [27-
30]. The majority of these studies derived utility scores
from the EQ-5D [27-29], while one study used the Qual-
ity of Well-Being Index [30]. Utility scores vary between
instruments, likely due to differences in the range of pos-
sible scores, method by which preferences are elicited and
the content of the instruments (i.e. the attributes of health
status captured, the number of levels for assessing degree
of impairment, and the weight given to each attribute in
calculating overall scores). Such differences have the
potential to affect the manner in which the instruments
behave in populations with diabetes, making some instru-
ments more sensitive to the health deficits specifically
associated with diabetes. It is necessary to assess the con-
struct validity of each preference-based measure, as results
from one instrument cannot be generalized to others. This
study provides the first evidence that the HUI3 captures
the HRQL burden of disease severity in type 2 diabetes.
It has been argued that generic measures of HRQL have an
advantage over specific measures in that they permit com-
parisons across disease states. Such information could
potentially be useful to assist with resource allocation and
policy decision making. Utility values obtained using dif-
ferent methods and different instruments vary considera-
bly for the reasons outlined previously, but may also vary
between study samples due to differences in demograph-
ics, clinical characteristics, etc. That said, it still may be
useful to compare utility values of other diseases
(obtained using the same instrument) to provide a frame
of reference for community preferences for the health
states associated with type 2 diabetes. For example, in a
population-based study using the HUI3, it was found that
the average overall HUI3 score for individuals with stroke
was 0.54 and arthritis was 0.77 [22]. In this study the aver-
age overall HUI3 score was 0.64 ± 0.30, suggesting the
average preference for health states associated with type 2
diabetes was less than stroke, but more than arthritis.
Direct comparisons are limited, however, as we did not
control for the number of additional comorbid medical
conditions while Grootendorst et al. did; other demo-
graphic differences between samples could be important
as well [22].
A number of limitations in this study should be recog-
nized. First, the number of individuals for which HRQL
data was missing was relatively large for some HRQL
measures and statistically significant differences between
individuals with complete and missing data for the vari-
ous HRQL measures were found. It is unclear how these
differences would affect study results. Individual missing
HRQL data were older and had lower socio-economic sta-
tus. It is possible that this systematic absence of data
would weaken several of the observed relationships and
understate the burden of diabetes. Further assessment of
the impact of missing data and imputation methods are
planned. As well, in carrying out a multivariate analysis,
individuals with missing data on covariates were excluded
from the analysis. For most analyses, no differences were
found in HRQL scores for individuals included in and
missing from the multivariate analyses. The exception to
this was the analysis according to absenteeism from work
due to diabetes. As no association was found between the
probability of being excluded and the grouping variable
(i.e. being absent from work), it is unlikely that the effect
of excluding subjects missing covariates biased the
between groups comparisons. However, since the
excluded individuals were healthier, the burden in both
groups may have been overstated for this particular
analysis.
Data on treatment for diabetes, emergency room visits
and absenteeism from work were based on self-report and
this could potentially be a study limitation. However, a
high level of agreement was observed between self-
reported treatment of diabetes and data obtained through
a formal medication history taken by research coordina-
tors for these patients, so data on treatment regimen is
likely reliable [34]. An additional limitation of the study
was the lack of direct data on the presence of complica-
tions, which has been shown in past research to be associ-
ated with HRQL in diabetes [28]. Instead, this study used
treatment intensity, emergency room visits and time off
work for diabetes, with the assumption that these varia-
bles were accurate markers for disease severity. It was then
assumed that more severe diabetes would be associated
with more complications. Unfortunately, data on compli-
cations was not collected as part of the larger study and
was not available. Another limitation of the study was the
relatively small number of individuals who reported
being absent from work or visiting an emergency room for
diabetes. Finally, it was not clear how representative this
sample was of the general population of individuals with
type 2 diabetes, although generalizing the study findings
beyond rural Albertans with type 2 diabetes was not the
purpose of this study. Rather, it was our objective to cap-
ture the disease burden of type 2 diabetes in rural Alber-
tans. As we are reasonably confident that our study
sample was representative of the target population [20],
we feel that this objective has been accomplished.
Conclusions
The PHC and MHC of the RAND-12, the overall HUI3
and diabetes relevant single attributes captured differ-
ences in burden associated with treatment regimen, emer-
gency room visits and absenteeism from work due to
diabetes. Glycated hemoglobin (HbA1c), a physiologicHealth and Quality of Life Outcomes 2003, 1 http://www.hqlo.com/content/1/1/78
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measure of average glycemic control, was not related to
the majority of the generic HQRL scores and did not ade-
quately reflect individuals' overall physical and mental
health. We believe that HBA1c is a nonspecific and insen-
sitive measure of disease burden in diabetes, despite it
being an important prognostic physiologic parameter. We
would encourage the use of HRQL measures to capture
the disease burden of type 2 diabetes, rather than focusing
on physiological parameters.
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